Phage-Antibiotic Cocktail Rescues Daptomycin and Phage Susceptibility against Daptomycin-Nonsusceptible Enterococcus faecium in a Simulated Endocardial Vegetation Ex Vivo Model

• Published in: Microbiology spectrum Vol. 11; no. 4; p. e0034023
• Main Authors: Kunz Coyne, Ashlan J, Stamper, Kyle, El Ghali, Amer, Kebriaei, Razieh, Biswas, Biswajit, Wilson, Melanie, Deschenes, Michael V, Tran, Truc T, Arias, Cesar A, Rybak, Michael J
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 17.08.2023
• Subjects: Anti-Bacterial Agents - pharmacology; antibiotic resistance; Antimicrobial Chemotherapy; bacteriophage; beta-Lactams - pharmacology; Ceftaroline; Daptomycin - pharmacology; Enterococcus; Enterococcus faecium; Humans; infective endocarditis; Microbial Sensitivity Tests; Research Article; Vancomycin - pharmacology; Enterococcus; infective endocarditis; antibiotic resistance; bacteriophage
• ISSN: 2165-0497; 2165-0497
• DOI: 10.1128/spectrum.00340-23

Enterococcus faecium is a difficult-to-treat pathogen with emerging resistance to most clinically available antibiotics. Daptomycin (DAP) is the standard of care, but even high DAP doses (12 mg/kg body weight/day) failed to eradicate some vancomycin-resistant strains. Combination DAP-ceftaroline (CPT) may increase β-lactam affinity for target penicillin binding proteins (PBP); however, in a simulated endocardial vegetation (SEV) pharmacokinetic/pharmacodynamic (PK/PD) model, DAP-CPT did not achieve therapeutic efficacy against a DAP-nonsusceptible (DNS) vancomycin-resistant E. faecium (VRE) isolate. Phage-antibiotic combinations (PAC) have been proposed for resistant high-inoculum infections. We aimed to identify PAC with maximum bactericidal activity and prevention/reversal of phage and antibiotic resistance in an SEV PK/PD model against DNS isolate R497. Phage-antibiotic synergy (PAS) was evaluated with modified checkerboard MIC and 24-h time-kill analyses (TKA). Human-simulated antibiotic doses of DAP and CPT with phages NV-497 and NV-503-01 were then evaluated in 96-h SEV PK/PD models against R497. Synergistic and bactericidal activity was identified with the PAC of DAP-CPT combined with phage cocktail NV-497-NV-503-01, demonstrating a significant reduction in viability down to 3-log CFU/g (-Δ, 5.77-log CFU/g; 0.001). This combination also demonstrated isolate resensitization to DAP. Evaluation of phage resistance post-SEV demonstrated prevention of phage resistance for PACs containing DAP-CPT. Our results provide novel data highlighting bactericidal and synergistic activity of PAC against a DNS E. faecium isolate in a high-inoculum SEV PK/PD model with subsequent DAP resensitization and prevention of phage resistance. Our study supports the additional benefit of standard-of-care antibiotics combined with a phage cocktail compared to antibiotic alone against a daptomycin-nonsusceptible (DNS) E. faecium isolate in a high-inoculum simulated endocardial vegetation PK/PD model. E. faecium is a leading cause of hospital-acquired infections and is associated with significant morbidity and mortality. Daptomycin is considered the first-line therapy for vancomycin-resistant E. faecium (VRE), but the highest published doses have failed to eradicate some VRE isolates. The addition of a β-lactam to daptomycin may result in synergistic activity, but previous data demonstrate that daptomycin plus ceftaroline failed to eradicate a VRE isolate. Phage therapy as an adjunct to antibiotic therapy has been proposed as a salvage therapy for high-inoculum infections; however, pragmatic clinical comparison trials for endocarditis are lacking and difficult to design, reinforcing the timeliness of such analysis.